Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F23%3A00014187" target="_blank" >RIV/75010330:_____/23:00014187 - isvavai.cz</a>
Result on the web
<a href="https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.4.2200340" target="_blank" >https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.4.2200340</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2807/1560-7917.ES.2023.28.4.2200340" target="_blank" >10.2807/1560-7917.ES.2023.28.4.2200340</a>
Alternative languages
Result language
angličtina
Original language name
Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
Original language description
Background: Timely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients. Aim: We assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20. Methods: Case-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained. A mixed effect logistic regression model using country as random intercept was applied to estimate the adjusted odds ratio (aOR) for in-hospital death in patients treated with NAIs vs not treated. Results: Of 19,937 patients, 31% received NAIs within 48 hours of hospital admission. Older age (60-79 years aOR 3.0, 95% CI: 2.4-3.8; 80 years 8.3 (6.6-10.5)) and intensive care unit admission (3.8, 95% CI: 3.4-4.2) increased risk of dying, while early hospital admission after symptom onset decreased risk (aOR 0.91, 95% CI: 0.90-0.93). NAI treatment initiation within 48 hours and up to 7 days reduced risk of dying (0-48 hours aOR 0.51, 95% CI: 0.45- 0.59; 3-4 days 0.59 (0.51-0.67); 5-7 days 0.64 (0.56- 0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); >= 80 years 0.51 (0.42-0.63)). Conclusion: NAI treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30303 - Infectious Diseases
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Euro Surveillance
ISSN
1025-496X
e-ISSN
1560-7917
Volume of the periodical
28
Issue of the periodical within the volume
4
Country of publishing house
SE - SWEDEN
Number of pages
11
Pages from-to
2200340
UT code for WoS article
000928250100002
EID of the result in the Scopus database
2-s2.0-85147046694